View in EDS

Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.

Saved in:
Bibliographic Details
Title: Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.
Authors: Prabhu SA; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada., Moussa O; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada., Gonçalves C; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada., LaPierre JH; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada., Chou H; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada., Huang F; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada., Richard VR; Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada., Ferruzo PYM; Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada., Guettler EM; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada., Soria-Bretones I; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Kirby L; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Gagnon N; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada., Su J; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada., Silvester J; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Krisna SS; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada., Rose AAN; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.; Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada., Sheppard KE; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia., Cescon DW; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; University of Toronto, Toronto, Ontario, Canada., Mallette FA; Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada.; Department of Medicine, Université de Montréal, Montréal, Québec, Canada., Zahedi RP; Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.; McGill Centre for Translational Research in Cancer, McGill University, Montréal, Québec, Canada., Borchers CH; Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.; Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada.; McGill Centre for Translational Research in Cancer, McGill University, Montréal, Québec, Canada., Del Rincon SV; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.; McGill Centre for Translational Research in Cancer, McGill University, Montréal, Québec, Canada., Miller WH; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.; McGill Centre for Translational Research in Cancer, McGill University, Montréal, Québec, Canada.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2023 Feb 01; Vol. 22 (2), pp. 192-204.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36722142
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Prabhu+SA%22">Prabhu SA</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Moussa+O%22">Moussa O</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Gonçalves+C%22">Gonçalves C</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22LaPierre+JH%22">LaPierre JH</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Chou+H%22">Chou H</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Huang+F%22">Huang F</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Richard+VR%22">Richard VR</searchLink>; Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Ferruzo+PYM%22">Ferruzo PYM</searchLink>; Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Guettler+EM%22">Guettler EM</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Soria-Bretones+I%22">Soria-Bretones I</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Kirby+L%22">Kirby L</searchLink>; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Gagnon+N%22">Gagnon N</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Su+J%22">Su J</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Silvester+J%22">Silvester J</searchLink>; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Krisna+SS%22">Krisna SS</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Rose+AAN%22">Rose AAN</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.; Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Sheppard+KE%22">Sheppard KE</searchLink>; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Cescon+DW%22">Cescon DW</searchLink>; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; University of Toronto, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Mallette+FA%22">Mallette FA</searchLink>; Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada.; Department of Medicine, Université de Montréal, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Zahedi+RP%22">Zahedi RP</searchLink>; Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.; McGill Centre for Translational Research in Cancer, McGill University, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Borchers+CH%22">Borchers CH</searchLink>; Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.; Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada.; McGill Centre for Translational Research in Cancer, McGill University, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Del+Rincon+SV%22">Del Rincon SV</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.; McGill Centre for Translational Research in Cancer, McGill University, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Miller+WH%22">Miller WH</searchLink>; Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.; Division of Experimental Medicine, McGill University, Montréal, Québec, Canada.; McGill Centre for Translational Research in Cancer, McGill University, Montréal, Québec, Canada.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2023 Feb 01; Vol. 22 (2), pp. 192-204.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36722142
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-22-0092
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 192
    Titles:
      – TitleFull: Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Prabhu SA
      – PersonEntity:
          Name:
            NameFull: Moussa O
      – PersonEntity:
          Name:
            NameFull: Gonçalves C
      – PersonEntity:
          Name:
            NameFull: LaPierre JH
      – PersonEntity:
          Name:
            NameFull: Chou H
      – PersonEntity:
          Name:
            NameFull: Huang F
      – PersonEntity:
          Name:
            NameFull: Richard VR
      – PersonEntity:
          Name:
            NameFull: Ferruzo PYM
      – PersonEntity:
          Name:
            NameFull: Guettler EM
      – PersonEntity:
          Name:
            NameFull: Soria-Bretones I
      – PersonEntity:
          Name:
            NameFull: Kirby L
      – PersonEntity:
          Name:
            NameFull: Gagnon N
      – PersonEntity:
          Name:
            NameFull: Su J
      – PersonEntity:
          Name:
            NameFull: Silvester J
      – PersonEntity:
          Name:
            NameFull: Krisna SS
      – PersonEntity:
          Name:
            NameFull: Rose AAN
      – PersonEntity:
          Name:
            NameFull: Sheppard KE
      – PersonEntity:
          Name:
            NameFull: Cescon DW
      – PersonEntity:
          Name:
            NameFull: Mallette FA
      – PersonEntity:
          Name:
            NameFull: Zahedi RP
      – PersonEntity:
          Name:
            NameFull: Borchers CH
      – PersonEntity:
          Name:
            NameFull: Del Rincon SV
      – PersonEntity:
          Name:
            NameFull: Miller WH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2023 Feb 01
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1